Y Intercept Hong Kong Ltd Makes New $510,000 Investment in Nurix Therapeutics, Inc. $NRIX

Y Intercept Hong Kong Ltd purchased a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 55,231 shares of the company’s stock, valued at approximately $510,000. Y Intercept Hong Kong Ltd owned about 0.07% of Nurix Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vestal Point Capital LP increased its position in Nurix Therapeutics by 77.7% during the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the company’s stock worth $22,780,000 after purchasing an additional 874,448 shares in the last quarter. Perceptive Advisors LLC boosted its stake in shares of Nurix Therapeutics by 268.7% during the 2nd quarter. Perceptive Advisors LLC now owns 1,096,985 shares of the company’s stock worth $12,495,000 after purchasing an additional 799,432 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Nurix Therapeutics by 84.1% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,391,638 shares of the company’s stock worth $15,851,000 after purchasing an additional 635,668 shares during the last quarter. Nikko Asset Management Americas Inc. grew its holdings in shares of Nurix Therapeutics by 83.8% during the second quarter. Nikko Asset Management Americas Inc. now owns 1,389,274 shares of the company’s stock worth $15,796,000 after buying an additional 633,304 shares in the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Nurix Therapeutics by 106.2% during the first quarter. Millennium Management LLC now owns 874,399 shares of the company’s stock valued at $10,388,000 after buying an additional 450,262 shares during the period.

Nurix Therapeutics Trading Down 1.8%

Shares of Nurix Therapeutics stock opened at $16.79 on Wednesday. The business’s fifty day moving average price is $18.49 and its 200 day moving average price is $13.45. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $22.50. The stock has a market capitalization of $1.29 billion, a P/E ratio of -5.52 and a beta of 1.96.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Wednesday, January 28th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.02. The company had revenue of $13.58 million during the quarter, compared to analyst estimates of $13.41 million. Nurix Therapeutics had a negative return on equity of 57.51% and a negative net margin of 314.90%. As a group, sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,661 shares of the business’s stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $16.60, for a total transaction of $60,772.60. Following the completion of the sale, the chief financial officer directly owned 45,427 shares in the company, valued at $754,088.20. The trade was a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Gwenn Hansen sold 4,895 shares of the stock in a transaction on Friday, January 30th. The stock was sold at an average price of $16.60, for a total transaction of $81,257.00. Following the completion of the sale, the insider directly owned 83,672 shares of the company’s stock, valued at $1,388,955.20. The trade was a 5.53% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on NRIX. Wall Street Zen cut shares of Nurix Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, October 11th. Oppenheimer decreased their price objective on Nurix Therapeutics from $30.00 to $28.00 and set an “outperform” rating on the stock in a report on Friday, October 10th. Piper Sandler upped their target price on Nurix Therapeutics from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Thursday, January 29th. BTIG Research reiterated a “buy” rating and set a $30.00 target price on shares of Nurix Therapeutics in a research report on Thursday, January 29th. Finally, Royal Bank Of Canada raised their price target on Nurix Therapeutics from $28.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $29.50.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.